Impact of Recurrence Score Assay Varies With Patient Age

This article originally appeared here.
Share this content:
Impact of Recurrence Score Assay Varies With Patient Age
Impact of Recurrence Score Assay Varies With Patient Age

WEDNESDAY, Nov. 25, 2015 (HealthDay News) -- For women with early-stage breast cancer, the impact of receipt of the 21-gene recurrence score (RS) assay varies with patient age, according to a study published online Nov. 23 in the Journal of Clinical Oncology.

Andrew J. Epstein, Ph.D., from the Philadelphia Veterans Affairs Medical Center, and colleagues used data from the Pennsylvania Cancer Registry to examine the correlations between RS assay receipt, subsequent chemotherapy use, and medical expenditures. Data were included for 7,287 women with early-stage breast cancer who underwent initial surgical treatment.

The researchers observed marked variations in the associations for RS receipt and outcome with patient age. In women younger than 55 years, RS use correlated with lower chemotherapy use (19.2 percent lower). Among women aged 75 to 84 years, RS use correlated with higher chemotherapy use (5.7 percent higher). Among women younger than 55 years, RS receipt correlated with lower adjusted one-year medical spending ($15,333 lower), while higher spending was seen for women aged 75 to 84 years ($3,489 higher).

"From a population perspective, the impact of RS testing on breast cancer treatment and health care costs is much greater in younger women," the authors write.

Several authors disclosed financial ties to the pharmaceutical, biotechnology, and health insurance industries.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »